104 related articles for article (PubMed ID: 3260071)
41. Human alpha-2-macroglobulin, characterization and trypsin binding. Purification methods, trypsin and plasmin complex formation.
Hamberg U; Stelwagen P; Ervast HS
Eur J Biochem; 1973 Dec; 40(2):439-51. PubMed ID: 4273635
[No Abstract] [Full Text] [Related]
42. Production and administration to dogs of aerosols of alpha-1-proteinase inhibitor.
Smith RM; Spragg RG
Am J Med; 1988 Jun; 84(6A):48-51. PubMed ID: 3260073
[TBL] [Abstract][Full Text] [Related]
43. Large-scale purification of high purity α1-antitrypsin from Cohn Fraction IV with virus inactivation by solvent/detergent and dry-heat treatment.
Huangfu C; Zhang J; Ma Y; Jia J; Li J; Lv M; Ma X; Zhao X; Zhang J
Biotechnol Appl Biochem; 2018 May; 65(3):446-454. PubMed ID: 29072333
[TBL] [Abstract][Full Text] [Related]
44. Pathogen safety and characterisation of a highly purified human alpha
Kee S; Weber D; Popp B; Nowak T; Schäfer W; Gröner A; Roth NJ
Biologicals; 2017 May; 47():25-32. PubMed ID: 28377078
[TBL] [Abstract][Full Text] [Related]
45. Human alpha 1-antitrypsin genetic polymorphism: PI N subtypes.
Sesboüé R; Vercaigne D; Charlionet R; Lefebvre F; Martin JP
Hum Hered; 1984; 34(2):105-13. PubMed ID: 6611291
[TBL] [Abstract][Full Text] [Related]
46. Human plasma alpha-cysteine proteinase inhibitor. Purification by affinity chromatography, characterization and isolation of an active fragment.
Gounaris AD; Brown MA; Barrett AJ
Biochem J; 1984 Jul; 221(2):445-52. PubMed ID: 6548132
[TBL] [Abstract][Full Text] [Related]
47. Purification and characterization of the two forms of human plasma alpha 2HS-glycoprotein.
Gejyo F; Schmid K
Biochim Biophys Acta; 1981 Nov; 671(1):78-84. PubMed ID: 6796128
[TBL] [Abstract][Full Text] [Related]
48. Studies on cystic fibrosis using isoelectric focusing. II. Demonstration of deficient proteolytic cleavage of alpha2-macroglobulin in cystic fibrosis plasma.
Wilson GB; Fudenberg HH
Pediatr Res; 1976 Feb; 10(2):87-96. PubMed ID: 54896
[TBL] [Abstract][Full Text] [Related]
49. Isolation of the "cystic fibrosis protein" from serum.
Barthe C; Carrere J; Figarella C; Guy-Crotte O
Clin Chem; 1989 Sep; 35(9):1901-5. PubMed ID: 2776314
[TBL] [Abstract][Full Text] [Related]
50. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).
McElvaney NG; Burdon J; Holmes M; Glanville A; Wark PA; Thompson PJ; Hernandez P; Chlumsky J; Teschler H; Ficker JH; Seersholm N; Altraja A; Mäkitaro R; Chorostowska-Wynimko J; Sanak M; Stoicescu PI; Piitulainen E; Vit O; Wencker M; Tortorici MA; Fries M; Edelman JM; Chapman KR;
Lancet Respir Med; 2017 Jan; 5(1):51-60. PubMed ID: 27916480
[TBL] [Abstract][Full Text] [Related]
51. Electrophoresis, crossed immunoelectrophoresis, and isoelectric focusing in agarose gels with reduced electroendosmotic flow.
Johansson BG; Hjertén S
Anal Biochem; 1974 May; 59(1):200-13. PubMed ID: 4407484
[No Abstract] [Full Text] [Related]
52. Pharmacokinetics and Biochemical Efficacy of an α
Li Z; Franke RM; Morris DN; Yel L
Pulm Ther; 2022 Sep; 8(3):311-326. PubMed ID: 36001294
[TBL] [Abstract][Full Text] [Related]
53. Identification of a contaminant protein in the purification of human factor V. Comparison of two purification methods.
Bruin T; Ockelford P; ten Cate JW; Sturk A; Breederveld C
Biochim Biophys Acta; 1983 Oct; 748(1):139-42. PubMed ID: 6615848
[TBL] [Abstract][Full Text] [Related]
54. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis.
Campos MA; Runken MC; Davis AM; Johnson MP; Stone GA; Buikema AR
Adv Ther; 2018 Apr; 35(4):467-481. PubMed ID: 29616482
[TBL] [Abstract][Full Text] [Related]
55. Pain and cyanosis associated with alpha 1-proteinase inhibitor.
Clark JA; Gross TP
Am J Med; 1992 Jun; 92(6):621-6. PubMed ID: 1534964
[TBL] [Abstract][Full Text] [Related]
56. A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products.
Cowden DI; Fisher GE; Weeks RL
Curr Med Res Opin; 2005 Jun; 21(6):877-83. PubMed ID: 15969888
[TBL] [Abstract][Full Text] [Related]
57. A general method for fractionation of plasma proteins. Dye-ligand affinity chromatography on immobilized Cibacron blue F3-GA.
Gianazza E; Arnaud P
Biochem J; 1982 Jan; 201(1):129-36. PubMed ID: 7082279
[TBL] [Abstract][Full Text] [Related]
58. Alpha-1 antitrypsin protease inhibitor typing in immobilized pH gradients.
Drobnies AE; Vaughan R
Ann Clin Lab Sci; 1993; 23(1):33-8. PubMed ID: 8430998
[TBL] [Abstract][Full Text] [Related]
59. An unusual type of alpha1-antitrypsin deficiency in a child.
Langley CE; Berninger RW; Wolfson SL; Talamo RC
Johns Hopkins Med J; 1979 May; 144(5):161-5. PubMed ID: 312969
[TBL] [Abstract][Full Text] [Related]
60. A new method for determination of alpha-1-antitrypsin phenotypes using isoelectric focusing on polyacrylamide gel slabs.
Allen RC; Harley RA; Talamo RC
Am J Clin Pathol; 1974 Dec; 62(6):732-9. PubMed ID: 4215312
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
